# Study of Efficacy and Safety of GR1501 in Patients with Radiographic Axial Spondyloarthritis

> **NCT05881785** · PHASE3 · COMPLETED · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 465 (actual)

## Conditions studied

- Axial Spondyloarthritis

## Interventions

- **BIOLOGICAL:** GR1501 low dose
- **BIOLOGICAL:** GR1501 high dose
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT05881785
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-13
- **Primary completion:** 2023-12-18
- **Final completion:** 2024-05-21
- **Target enrollment:** 465 (ACTUAL)
- **Last updated:** 2024-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05881785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05881785, "Study of Efficacy and Safety of GR1501 in Patients with Radiographic Axial Spondyloarthritis". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05881785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*